Diseases
Disease Market Research, Intelligence and Forecasts
In this section you will find information products, including market research, covering disease research, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2010 | £11400 |
|
Antidiabetics in Australia Market Forecast |
October 2010 | £5700 |
|
Commercial Insight: Antidiabetics in Australia Reimbursement status shapes novel classes |
October 2010 | £5700 |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2035 |
|
Targeting Cancer Stem Cells Emerging Therapeutic, Therapeutic Strategies and Pipeline Developments (2010) |
January 2010 | £1599 |
|
Diabetes Market Forecast to 2015 |
January 2010 | £6360 |
|
The Cancer Market Outlook To 2014 Competitive landscape, market size, pipeline analysis and growth opportunities |
January 2010 | £3835 |
|
Treating Neuropathic Pain A Global Study of Clinical Strategies |
January 2010 | £3950 |
|
The Future of The Diabetes Care Devices Market to 2016 The Key Demand Drivers Remain Intact |
January 2010 | £2230 |
|
Cancer Vaccines Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Head and Neck Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Brain Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies |
January 2010 | £3490 |
|
Analytical Tool: Lymphoma Therapeutics & Competitive Insights |
January 2010 | £2705 |
|
Prostate Cancer - A Therapeutic & Competitive Insight Pipeline Update 2010 |
January 2010 | £1310 |
|
Analytical Tool: Prostate Cancer A Therapeutic & Competitive Insight |
January 2010 | £2705 |
|
Analytical Tool – Hematological Cancers |
January 2010 | £5190 |
|
Analytical Tool: Competitive Outlook on Cancer Vaccines |
January 2010 | £2705 |
|
Analytical Tool: Current & Future Lung Cancer Therapeutics |
January 2010 | £2705 |
|
Bladder Cancer Drug Pipeline Update 2010 |
January 2010 | £870 |
|
Analytical Tool - Leukemia Therapeutics & Competitive Insights |
January 2010 | £2705 |
|
Lung Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Analytical Tool - Targeted Therapeutics: Melanoma |
January 2010 | £2705 |
|
Liver Cancer Drug Pipeline Update 2010 |
January 2010 | £870 |
|
Analytical Tool - Colorectal Cancer |
January 2010 | £2705 |
|
Ovarian Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Pancreatic Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Colorectal Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Analytical Tool: Breast Cancer R&D Comprehensive Guide |
January 2010 | £2705 |
|
Analytical Tool: Analysis of Cancer Immunotherapy The World Guide |
January 2010 | £4320 |
|
Hematological Cancers Drug Pipeline Update 2010 |
January 2010 | £1745 |
|
Breast Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Renal Cancer Drug Pipeline Update 2010 |
January 2010 | £1310 |
|
Global Peritoneal Dialysis Market Strategic Analysis and Opportunity Assessment |
January 2010 | £2230 |
|
The US Cardiac Resynchronization Therapy Market Positive Clinical Trial Results to Boost Growth |
December 2009 | £320 |
|
The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
December 2009 | £2230 |
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis |
November 2009 | £950 |
|
The World Dermatological Market Outlook 2010-2024 |
November 2009 | £1499 |
|
Infectious Disease Testing Instrumentation Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers |
November 2009 | £450 |
|
Leading Infectious Disease Market Players Insightful Profiles of Major Suppliers and Recent Market Entrants |
November 2009 | £1080 |
|
Infectious Disease Testing Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks |
November 2009 | £300 |
|
Italian Infectious Disease Testing Market |
November 2009 | £3305 |
|
Japanese Infectious Disease Testing Market |
November 2009 | £4210 |
|
Infectious Disease Testing Technologies Market Applications of Current and Emerging Technologies |
November 2009 | £510 |
|
Current and Emerging Infectious Disease Tests Emerging Assays and Companies Developing New Technologies and Products |
November 2009 | £2315 |
|
Thrombopoiesis-Stimulating Agents (TPO) Competitor Analysis |
November 2009 | £130 |
|
TGF-R Agonists and Antagonists Competitor Analysis |
November 2009 | £175 |
|
FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART) Competitor Analysis |
November 2009 | £175 |
|
CXCR and CXCL Agonists and Antagonists Competitor Analysis |
November 2009 | £260 |
|
Spanish Infectious Disease Testing Market |
November 2009 | £3305 |
|
German Infectious Disease Testing Market |
November 2009 | £3305 |
|
French Infectious Disease Testing Market |
November 2009 | £3305 |
|
Global Infectious Disease Testing Market Facilities, Test Volume, and Sales Forecasts by Country |
November 2009 | £510 |
|
US Infectious Disease Testing Market |
November 2009 | £5650 |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1905 |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1905 |
|
CNS Therapeutics A World Market Review |
November 2009 | £1905 |
|
Cancer Therapies Global Market Opportunities |
November 2009 | £1905 |
|
UK Infectious Disease Testing Market |
November 2009 | £3305 |
|
Pain Management Global Trends |
November 2009 | £1905 |
|
Monoclonal Antibody Based Products Global Trends |
November 2009 | £1905 |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1905 |
|
Hiv/Aids Testing World Review |
November 2009 | £1905 |
|
Cardiovascular Disease Diagnostics A World Market Intelligence Report |
November 2009 | £1905 |
|
Cholesterol and Other Cardiovascular Testing Trends & Opportunities Worldwide |
November 2009 | £1905 |
|
Diabetes Diagnostics A Global Market Perspective |
November 2009 | £1905 |
|
Hemoglobin A1c Monitoring Global Market Trends |
November 2009 | £1905 |
|
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010 |
November 2009 | £4770 |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1910 |
|
Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The |
October 2009 | £2230 |
|
Infectious Diseases Drugs Markets |
October 2009 | £2165 |
|
European Markets for Interventional Cardiology (15 Countries) 2009 |
October 2009 | £7315 |
|
Competitor Analysis: EGF-R Agonists and Antagonists |
October 2009 | £260 |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1910 |
|
Chinese Markets for Colon Cancer Treatment Drugs |
September 2009 | £2545 |
|
Chinese Markets for Cervical Cancer Treatment Drugs |
September 2009 | £2545 |
|
Chinese Markets for Bladder Cancer Treatment Drugs |
September 2009 | £2545 |
|
Chinese Markets for Brain Cancer Treatment Drugs |
September 2009 | £2545 |
|
Competitor Analysis: Her2 Receptor Antagonists |
September 2009 | £220 |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 |
|
Cancer Diagnostic Testing Instrumentation Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers |
September 2009 | £320 |
|
Cancer Diagnostic Testing A Global Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country |
September 2009 | £415 |
|
Cancer Diagnostics Market New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks |
September 2009 | £320 |
|
Cancer Diagnostic Technologies Assessment of Current and Emerging Technologies, and Their Potential Market Applications |
September 2009 | £1080 |
|
The US Cancer Diagnostics Market |
September 2009 | £4710 |
|
The Italian Cancer Diagnostics Market |
September 2009 | £2610 |
|
The Spanish Cancer Diagnostics Market |
September 2009 | £2610 |
|
The UK Cancer Diagnostics Market |
September 2009 | £2610 |
|
The German Cancer Diagnostics Market |
September 2009 | £2610 |
|
The Japanese Cancer Diagnostics Market |
September 2009 | £3630 |
|
Leading Cancer Diagnostics Market Players Strategic Assessments of Major Suppliers and Emerging Market Entrants |
September 2009 | £1400 |
|
Current and Emerging Cancer Diagnostic Tests Emerging Assays and Companies Developing New Technologies and Products |
September 2009 | £1815 |
|
The French Cancer Diagnostics Market |
September 2009 | £2610 |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2140 |
|
CHK and KSP/Eg5 Inhibitors Competitor Analysis |
August 2009 | £155 |
|
Osteoporosis Market Forecast |
July 2009 | £15200 |
|
Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
July 2009 | £15200 |
|
IGF-1R Antagonists Competitor Analysis |
July 2009 | £220 |
|
Bcr-Abl Kinase Inhibitors Competitor Analysis |
July 2009 | £175 |
|
Immunotoxins Competitor Analysis |
July 2009 | £130 |
|
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis |
July 2009 | £435 |
|
HDAC Inhibitors Competitor Analysis |
July 2009 | £350 |
|
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 |
July 2009 | £1499 |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1700 |
|
Rapid Advances in HIV/AIDS Clinical Diagnostics |
June 2009 | £4135 |
|
HIV Market Forecast |
June 2009 | £15200 |
|
Chinese Markets for Blood Disease Drugs |
June 2009 | £2440 |
|
Immunocytokines Competitor Analysis |
June 2009 | £130 |
|
MEK Inhibitors Competitor Analysis |
June 2009 | £130 |
|
Aurora Kinase Inhibitors Competitor Analysis |
June 2009 | £155 |
|
Chinese Markets for Hepatitis Treatment Drugs |
June 2009 | £2440 |
|
Chinese Markets for Leukemia Treatment Drugs |
June 2009 | £2440 |
|
Chinese Markets for Asthma Treatment Drugs |
June 2009 | £2440 |
|
Insulin Delivery Devices Market Analysis and Future Forecast |
June 2009 | £475 |
|
Asthma and COPD Market Forecast |
June 2009 | £15200 |
|
Allergy Drug Pipeline and R&D 2009 Emerging Technologies, Companies, Products, Applications, Sales & Market Share, and Worldwide Outlook |
June 2009 | £665 |
|
Forecast Insight: HIV |
June 2009 | £15200 |
|
Chinese Markets for Anti-Infectious Disease Drugs |
June 2009 | £2440 |
|
Global Cardiovascular Drugs Market 2009-2024 |
June 2009 | £1499 |
|
Antibody-Drug Conjugates (ADC) Competitor Analysis |
June 2009 | £220 |
|
Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize? |
May 2009 | £3010 |
|
Rheumatoid Arthritis Market Competitive Landscape and Clinical Stage Analysis |
May 2009 | £950 |
|
Plk-1 Inhibitors Competitor Analysis |
May 2009 | £87 |
|
Raf Inhibitors Competitor Analysis |
May 2009 | £175 |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1780 |
|
Ras-Raf-MEK-ERK Inhibitors Competitor Analysis |
May 2009 | £305 |
|
Elastase Inhibitors Competitor Analysis |
May 2009 | £175 |
|
Swine Influenza Market Alert (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) |
May 2009 | £510 |
|
Novel Mitotic Kinase Inhibitors Competitor Analysis |
May 2009 | £305 |
|
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The |
May 2009 | £2545 |
|
China Asthma Drug Market Report The Chinese Asthma Drug Drug Utilization |
May 2009 | £2865 |
|
Alzheimer's Disease:Markets, Pipeline and Opportunities 2009 |
April 2009 | £1855 |
|
PARP Inhibitors Competitor Analysis |
April 2009 | £87 |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1700 |
|
Hypoxia-Inducible Factor (HIF) Competitor Analysis |
April 2009 | £87 |
|
Blood Glucose Testing and Diabetes Management |
April 2009 | £2165 |
|
U.S. Market for Interventional Cardiology 2009 |
April 2009 | £4250 |
|
InvestFrost Chemicals - U.S. Heart Health Ingredients Market |
April 2009 | £3820 |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £6000 |
|
Sphingosine-1-Phosphate (S1P) Competitor Analysis |
April 2009 | £87 |
|
CD3 Antagonists Competitor Analysis |
March 2009 | £175 |
|
The Global Multiple Sclerosis Market 2009-2024 |
March 2009 | £1499 |
|
Attention-Deficit Hyperactivity Disorder (ADHD) Competitor Analysis |
March 2009 | £175 |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £2000 |
|
Stakeholder Insight: Psoriasis Biologics are yet to make topical treatments obsolete |
March 2009 | £8000 |
|
The World Diabetes Market, 2007-2025 An Analysis of Diabetes Drug and Insulin Market |
March 2009 | £225 |
|
China Senile Dementia Drug Market Report The Chinese Dementia Drug Utilization |
March 2009 | £5090 |
|
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success Healthcare |
March 2009 | £2000 |
|
EpCAM Antagonists Competitor Analysis |
March 2009 | £87 |
|
Stakeholder Opinions: Back Pain Gain competitive edge by targeting subpopulations |
March 2009 | £2000 |
|
Opioids Market Forecast Healthcare |
March 2009 | £8000 |
|
China Allergy Drug Market Report The Chinese Allergy Cancer Drug Utilization |
March 2009 | £2865 |
|
Amyotrophic Lateral Sclerosis/ Lou Gehrig's disease Competitor Analysis |
March 2009 | £175 |
|
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare |
March 2009 | £2000 |
|
Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment |
March 2009 | £190 |
|
Overview of General Hospital Consumables and Cardiovascular Products Market in Sri Lanka |
March 2009 | £3820 |
|
Strategic Analysis of Optical Imaging Technologies in U.S. Clinical Diagnostics and Drug Discovery Markets |
March 2009 | £3820 |
|
The Toolkit for Diabetes MSL Programs |
March 2009 | £4900 |
|
Opportunities Assessment for Hepatitis B Therapeutics Market in Indonesia |
March 2009 | £3820 |
|
Wet Age-Related Macular Degeneration (AMD) Competitor Analysis |
February 2009 | £260 |
|
Inflammatory Bowel Diseases World Market Report 2009-2024 |
February 2009 | £1499 |
|
World Diabetes Market Analysis 2009-2023 |
February 2009 | £1499 |
|
Diabetes Drug Discoveries 2009: what the future holds |
February 2009 | £795 |
|
China Dermatosis Drug Market Report The Chinese Hospital Cancer Drug Utilization |
February 2009 | £5090 |
|
China Hypertension Drug Market Report The Chinese Hospital Cancer Drug Utilization |
February 2009 | £5090 |
|
Commercial Insight: Cardiovascular and metabolic market overview Diabetes to the fore as generics hit primary care markets |
February 2009 | £8000 |
|
Neurodegenerative Market Forecast to 2013 |
February 2009 | £6360 |
|
Cancer Market Trends 2008 - 2012 Key market forecasts and growth opportunities |
January 2009 | £1100 |
|
Alzheimer's Disease Biomarkers, 2009 |
January 2009 | £1499 |
|
China Diabetes Drug Market Report The Chinese Hospital Cancer Drug Utilization |
January 2009 | £5090 |
|
Hematological Cancers Drug Pipeline Update 2009 |
January 2009 | £1745 |
|
Anti-Infective Peptides Competitor Analysis |
January 2009 | £260 |
|
Analytical Tool - Cancer Therapeutic Antibodies |
January 2009 | £3580 |
|
Analytical Tool - Breast Cancer |
January 2009 | £2705 |
|
Analytical Tool - Apoptosis in Oncology |
January 2009 | £2705 |
|
Cancer Vaccines Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Stem Cells for Cardiovascular Disease 2009 Market Report |
January 2009 | £2000 |
|
Analytical Tool - Angiogenesis in Oncology |
January 2009 | £2705 |
|
Breast Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £2000 |
|
CD20 Antibodies Competitor Analysis |
January 2009 | £175 |
|
Leukemia Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
PTH Receptor Agonists Competitor Analysis |
January 2009 | £130 |
|
Colorectal Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Protein Kinase C (PKC) Inhibitors Competitor Analysis |
January 2009 | £175 |
|
C5a-R Antagonists Competitor Analysis |
January 2009 | £110 |
|
Liver Cancer Drug Pipeline Update 2009 |
January 2009 | £870 |
|
Lymphoma Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Lung Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Analytical Tool - Protein Kinase Inhibitors in Oncology |
January 2009 | £2705 |
|
Melanoma Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
European Market for Cadiac Rhythm Management, Electrophysiology, and Ablation Devices 2009 (15 Countries) |
January 2009 | £7315 |
|
Analytical Tool - Cancer Vaccines |
January 2009 | £2705 |
|
Ovarian Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Pancreatic Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
The Cardiovascular Market Outlook to 2013 Competitive Landscape, Global Market Analysis and Pipeline Analysis |
January 2009 | £2025 |
|
Bladder Cancer Drug Pipeline Update 2009 |
January 2009 | £870 |
|
Analytical Tool - Prostate Cancer A Therapeutic & Competitive Insight |
January 2009 | £2705 |
|
Brain Cancer Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
Angiogenesis in Oncology Drug Pipeline Update 2009 |
January 2009 | £1310 |
|
U.S. Markets for Cardiac Rhythm Management, Electrophysiology, and Ablation Devices 2008 |
January 2009 | £4770 |
|
Analytical Tool - Melanoma |
January 2009 | £2705 |
|
European Point of Care (POC) Infectious Disease Market |
December 2008 | £3820 |
|
China Anti-Cancer Drug Market Report The Chinese Hospital Cancer Drug Utilization |
December 2008 | £5090 |
|
U.S. Market for Peripheral Vascular Devices 2009 |
December 2008 | £4770 |
|
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders |
December 2008 | £2385 |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1910 |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £8000 |
|
Enzyme Replacement & Enhancement Therapies (ERT) Competitor Analysis |
November 2008 | £220 |
|
Interferon Competitor Analysis |
November 2008 | £350 |
|
The Global Pain Market 2008-2023 |
November 2008 | £1499 |
|
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail |
November 2008 | £4000 |
|
Stakeholder Opinions: Diabetic Renal Disease |
November 2008 | £2000 |
|
MarketWatch: CNS |
November 2008 | £105 |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1045 |
|
Diabetes Market Forecast to 2013 |
November 2008 | £6360 |
|
Dipeptidyl peptidase IV (DPP-IV) Inhibitors Competitor Analysis |
November 2008 | £130 |
|
Emerging Diabetes Drugs Competitor Analysis |
November 2008 | £525 |
|
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Competitor Analysis |
November 2008 | £260 |
|
GLP-1 Receptor Agonists Competitor Analysis |
November 2008 | £175 |
|
Sodium-dependent glucose (co-) transporter (SGLT) Inhibitors Competitor Analysis |
November 2008 | £87 |
|
MarketWatch: Cancer |
November 2008 | £105 |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £8000 |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £8000 |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 |
|
Insulin Competitor Analysis |
October 2008 | £350 |
|
R&D Pipeline News - Technology Edition: 1-Month Subscription Periodical |
October 2008 | £87 |
|
R&D Pipeline News - Technology Edition: 1-Year Subscription Periodical |
October 2008 | £700 |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription Periodical |
October 2008 | £87 |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Year Subscription Periodical |
October 2008 | £700 |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 |
|
Austrian Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
U.K. Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
Spanish Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
The CNS Market Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
September 2008 | £1995 |
|
U.S. Cardiovascular Business Digest - AAA Stent Grafts Market |
September 2008 | £2480 |
|
Scandinavian Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
Swiss Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1700 |
|
French Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
European Markets for Vascular Access Devices 2008 (15 Countries) |
September 2008 | £7315 |
|
German Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
Portuguese Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
U.S. Market for Vascular Access Devices & Accessories 2008 |
September 2008 | £4770 |
|
Beneluxian Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
Italian Market for Vascular Access Devices 2008 |
September 2008 | £2860 |
|
U.S. Cardiovascular Business Digest - Drug Eluting Stent Market |
September 2008 | £2480 |
|
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 |
August 2008 | £1499 |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1700 |
|
Global Cancer Treatment Forecast to 2012 |
August 2008 | £1020 |
|
Cancer Therapeutics Market Insight and R&D Pipeline Analysis |
August 2008 | £2230 |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2385 |
|
Erythropoietin (EPO) Competitor Analysis |
July 2008 | £350 |
|
Cytology and HPV Testing World Markets |
July 2008 | £2165 |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 |
|
Cancer Antibodies Competitive Positioning for Success |
June 2008 | £1700 |
|
Cancer Antibodies: Competitive Positioning for Success |
June 2008 | £1700 |
|
Innovations in The Management of Diabetes Next generation treatments and market dynamics |
June 2008 | £1995 |
|
Pipeline Insight: Acute Stroke Commercial Risk Offsets High Unmet Need |
May 2008 | £6000 |
|
Cancer Therapeutics Markets |
May 2008 | £2165 |
|
Cancer Vaccines: Aim and Shoot |
May 2008 | £1700 |
|
Cardiac Marker Diagnostic Testing Markets |
May 2008 | £2165 |
|
NGF Agonists and Antagonists Competitor Analysis |
May 2008 | £87 |
|
CNS Generic Drugs: Prospects and Opportunities to 2012 |
April 2008 | £995 |
|
Stakeholder Opinions: Percutaneous Coronary Intervention Adverse events with drug-eluting stents demand a new safety standard |
April 2008 | £2005 |
|
Stakeholder Opinions: Heart Failure When drugs do not work |
April 2008 | £2005 |
|
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market |
April 2008 | £8000 |
|
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors |
April 2008 | £8000 |
|
Commercial and Pipeline Insight: ADHD Immature adult market continues to offer greatest commercial potential |
April 2008 | £8000 |
|
Inflammatory Directions Strategies for Six Diseases with Unmet Needs |
April 2008 | £715 |
|
Cancer Diagnostic Testing World Markets |
April 2008 | £2165 |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2165 |
|
Pipeline and Commercial Insight: Alzheimer's Disease Scenario Forecasts Reveal Vast Market Potential |
March 2008 | £7600 |
|
Stakeholder Opinions: Sepsis The Critical Care Community Gains Critical Mass |
March 2008 | £2050 |
|
Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success |
March 2008 | £2005 |
|
Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents |
March 2008 | £2005 |
|
Stakeholder Opinions: Systemic Lupus Erythematosus Market Set to Enter Era of Biologic Therapies |
March 2008 | £2050 |
|
Cancer Cell Therapy Markets |
March 2008 | £2165 |
|
Cardiac Toxicity |
March 2008 | £1495 |
|
The Worldwide Market for Cancer Diagnostics 3rd Edition |
March 2008 | £2545 |
|
Hypertension, Antihypertensive Treatment and Heart Failure 2nd Edition |
March 2008 | £149.95 |
|
Textbook of Lung Cancer |
March 2008 | £115 |
|
Treatment Methods for Early and Advanced Prostate Cancer |
March 2008 | £99 |
|
HIV and Aging |
March 2008 | £55 |
|
Manual of Hypertension of the European Society of Hypertension |
March 2008 | £99.95 |
|
Free Radicals in Ophthalmic Disorders |
March 2008 | £256 |
|
Lyme Disease in North America and Europe |
March 2008 | £115 |
|
Clinical Protocols in Obstetrics and Gynecology |
February 2008 | £55 |
|
Anesthesia and Analgesia in Dermatologic Surgery Series: Basic and Clinical Dermatology |
February 2008 | £115 |
|
The Cardiovascular Disorders Market Outlook to 2012 |
February 2008 | £1995 |
|
The Epidemiology of Diabetes in Youth |
February 2008 | £115 |
|
ESMO Handbook of Cancer Prevention European Society for Medical Oncology Handbooks |
February 2008 | £22.5 |
|
Textbook of Diabetes and Pregnancy |
February 2008 | £140 |
|
Hair and Scalp Diseases Medical, Surgical, and Cosmetic Treatments |
February 2008 | £115 |
|
Cancer Therapies: Technologies and Global Markets |
January 2008 | £3085 |
|
Diabetes Therapies & Diagnostics: Global Markets |
January 2008 | £3085 |
|
Pharmacological and Psychosocial Treatments in Schizophrenia |
January 2008 | £35.95 |
|
The Cancer Market Outlook to 2012 |
January 2008 | £1995 |
|
Reflectance Confocal Microscopy of Cutaneous Tumors An Atlas with Clinical, Dermoscopic and Histological Correlations |
January 2008 | £129.95 |
|
Peripheral Neuropathy and Neuropathic Pain, 2008 Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain |
January 2008 | £1499 |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 |
|
Urinary Incontinence - Lifecycle Management Strategies Retain Mid-Term Market Growth Pipeline And Commercial Insight |
December 2007 | £7600 |
|
Infectious Diseases Overview Commercial Insight |
December 2007 | £7600 |
|
Acute Coronary Syndromes Fresh Look At Acs In Europe, What Is The Real Picture? Stakeholder Insight |
December 2007 | £15200 |
|
Autoimmune Overview - Market Continues To Prosper Commercial Insight |
December 2007 | £7600 |
|
Diabetes Stakeholder Insight |
December 2007 | £7600 |
|
Orphan Diseases In CNS - Part II Amyotrophic Lateral Sclerosis Pipeline Insight |
December 2007 | £3800 |
|
Parkinson's Disease - Evidence Of Neuroprotection Essential To Progress Treatment Dynamics Stakeholder Insight |
December 2007 | £7600 |
|
Hepatitis C - Small-Molecule Antivirals Pave The Way For Triple Therapy Stakeholder Opinions |
December 2007 | £2005 |
|
Non-Hodgkin's Lymphoma - Is There Room To Emulate Rituxan's Success? Stakeholder Opinions |
December 2007 | £2005 |
|
Myelodysplastic Syndromes - First Approvals Spur Some Interest In A Niche Market Stakeholder Opinions |
December 2007 | £2005 |
|
Inflammatory Bowel Disease - Debate Over Early Aggressive Treatment Continues Stakeholder Insight |
December 2007 | £7600 |
|
HIV - Novel Nnrtis Address Crucial Unmet Need Pipeline Insight |
December 2007 | £6000 |
|
Peripheral Artery Disease Poor Disease Awareness Hinders New Agents Pipeline Perspectives |
December 2007 | £3800 |
|
Endometriosis - Scientific Clarity Will Unlock Market Potential Stakeholder Opinions |
December 2007 | £2005 |
|
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy Stakeholder Opinions |
December 2007 | £2005 |
|
Substance Dependence - Part II: Alcohol Pipeline Insight |
December 2007 | £3800 |
|
Parkinson's Disease in Focus |
December 2007 | £29.95 |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £2005 |
|
Who's Developing What in New Cancer Drugs 2006? |
November 2007 | £495 |
|
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease |
November 2007 | £3800 |
|
Pipeline Insight Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
November 2007 | £3010 |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £7600 |
|
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology |
November 2007 | £1710 |
|
US Market for Interventional Cardiology 2008 |
November 2007 | £4770 |
|
Japanese Market for Peripheral Vascular 2008 |
November 2007 | £4770 |
|
Type 1 Diabetes in Adults Principles and Practice |
November 2007 | £105 |
|
Stakeholder Insight Alzheimer's Disease PharmaVitae Profile |
October 2007 | £3010 |
|
Pipeline Insight Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
October 2007 | £3010 |
|
The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape |
October 2007 | £1910 |
|
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market? - Cancer |
October 2007 | £7600 |
|
Multiple Myeloma |
October 2007 | £105 |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £7600 |
|
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward |
September 2007 | £7600 |
|
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market |
September 2007 | £740 |
|
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits |
September 2007 | £7600 |
|
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack |
September 2007 | £7600 |
|
Cancer Vaccine Developments to 2011 |
September 2007 | £1296 |
|
Neurological Complications of Systemic Cancer |
September 2007 | £115 |
|
Prognostic and Predictive Factors in Gynecologic Cancers |
September 2007 | £55 |
|
Innovations in Cardiovascular Disease Management Latest surgical procedures, drugs and medical devices |
September 2007 | £1495 |
|
Hereditary Breast Cancer |
September 2007 | £105 |
|
Global Hepatitis Strategies |
August 2007 | £2545 |
|
Cancer-Associated Thrombosis |
August 2007 | £115 |
|
Skull Based Tumors |
August 2007 | £230 |
|
Image-Guided Radiotherapy of Lung Cancer |
August 2007 | £130 |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £7600 |
|
Melanoma - Targeted Therapeutics |
July 2007 | £1360 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC |
July 2007 | £2410 |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £2005 |
|
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence |
July 2007 | £3800 |
|
Commercial Insight: Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006 |
July 2007 | £7600 |
|
The Global HIV/Aids Market Outlook To 2012 |
July 2007 | £1495 |
|
Chronic Pain Management: Guidelines for Multidisciplinary Program Development |
July 2007 | £85 |
|
Clinical Pathology of Urological Tumours |
July 2007 | £125 |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 |
|
Commercial Insight: Osteoporosis Risk management and reformulation offer best defense against generic onslaught |
June 2007 | £7600 |
|
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment |
June 2007 | £7600 |
|
Commercial Insight: Depression Atypical lifecycle management strategy rejuvenates depression market |
June 2007 | £7600 |
|
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking |
June 2007 | £1900 |
|
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking |
June 2007 | £1900 |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 |
|
Stakeholder Opinions: Hepatocellular Carcinoma Opportune indication for novel therapies |
June 2007 | £3800 |
|
China Anti-tumor Drugs Market Report 2007 |
June 2007 | £190 |
|
Stakeholder Opinions: Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey |
June 2007 | £2005 |
|
Japanese Markets for Interventional Cardiology 2007 |
June 2007 | £4770 |
|
Antibody Drug Target Atlas in Oncology |
June 2007 | £1710 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2410 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas |
June 2007 | £2410 |
|
Global Tuberculosis Strategies |
June 2007 | £2545 |
|
Type 2 Diabetes, 2nd edition Principles and Practice |
June 2007 | £100 |
|
Multiple Sclerosis World Market Outlook to 2011 |
June 2007 | £1905 |
|
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
June 2007 | £995 |
|
Prostate Cancer Drug Pipeline Update 2009 |
May 2007 | £1310 |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2009 |
May 2007 | £1310 |
|
Renal Cancer Drug Pipeline Update 2009 |
May 2007 | £1310 |
|
Analytical Tool - Current & Future Lung Cancer Therapeutics |
May 2007 | £2705 |
|
Analytical Tool - Analysis of Cancer Immunotherapy The World Guide |
May 2007 | £4320 |
|
Analytical Tool - Lymphoma Therapeutics & Competitive Insights |
May 2007 | £2705 |
|
Analytical Tool - Hematological Cancers |
May 2007 | £5190 |
|
Atlas of Alzheimer's Disease |
May 2007 | £0 |
|
Lung Cancer Translational and Emerging Therapies |
May 2007 | £100 |
|
Parkinson's Disease Genetics and Pathogenesis |
May 2007 | £0 |
|
Geriatric Diabetes |
May 2007 | £105 |
|
Non-Small Cell Lung Cancer Drug Pipeline Update 2007 |
April 2007 | £1310 |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer |
April 2007 | £1360 |
|
Global Cancer Focus Company Directory |
April 2007 | £1360 |
|
Islet Transplantation and Beta, Cell Replacement therapy |
April 2007 | £145 |
|
Stakeholder Opinions: Asthma Phenotypes A changing paradigm |
March 2007 | £2005 |
|
GSK's Cervarix A Future Blockbuster of 2007 |
March 2007 | £1999 |
|
Stakeholder Opinions: Nosocomial Infections The need for new gram-negative drugs |
March 2007 | £2005 |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £6000 |
|
Stakeholder Opinion: Atopic Dermatitis A high level of unmet need creates market opportunities |
March 2007 | £2005 |
|
AMD Market Outlook to 2012 |
March 2007 | £1299 |
|
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs |
March 2007 | £2005 |
|
Global Pipeline Review & Analysis of Hematological Malignancies |
March 2007 | £2060 |
|
Prostate and Breast Cancer New Treatments & Developmental Progress |
March 2007 | £2060 |
|
Diabetes and Diabetic Complications Major World Markets, 3rd Ed. |
March 2007 | £2545 |
|
Immunotherapy of Cancer |
March 2007 | £3085 |
|
Litt's Drug Eruption Reference Manual, 13th edition Including Drug Interactions |
March 2007 | £0 |
|
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 |
February 2007 | £1499 |
|
Breast Cancer Therapeutic And Competitive Insights |
February 2007 | £1360 |
|
Breast Cancer - Therapeutic And Competitive Insights |
February 2007 | £1360 |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 |
|
Cancer Therapeutics: The Worldwide Market The Worldwide Market , 2nd Editon |
February 2007 | £2545 |
|
Drug Treatments for Leading Endocrine and Metabolic Diseases |
February 2007 | £3085 |
|
Diabetes Drug Discoveries What the Future Holds |
January 2007 | £1495 |
|
Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
January 2007 | £2005 |
|
World market for cancer vaccines 2007-2012 |
January 2007 | £1999 |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £6065 |
|
Commercial Insight: Osteoarthritis Market sees steady growth |
December 2006 | £8000 |
|
Stakeholder Insight: Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice |
December 2006 | £8000 |
|
Commercial and Pipeline Insight: Psoriasis Anti-TNF's lead another indication |
December 2006 | £8000 |
|
Stakeholder Opinion: Erectile Dysfunction Identifying product differentiation and patient segmentation strategies |
December 2006 | £2005 |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £2005 |
|
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
December 2006 | £2005 |
|
Stakeholder Insight: Atherosclerosis HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment |
December 2006 | £8000 |
|
Commercial Insight: Antibacterials Growth in resistance rates drives niche indications |
December 2006 | £8000 |
|
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
December 2006 | £6000 |
|
Commercial and Pipeline Perspectives: Obesity Lack of Reimbursement Limits Market Potential |
December 2006 | £6000 |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £8000 |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4320 |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £6000 |
|
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
December 2006 | £2005 |
|
Stakeholder Insight: Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value? |
December 2006 | £6000 |
|
Competitive Outlook on Apoptosis in Oncology |
December 2006 | £1700 |
|
World Market for Pain Management Drugs and Devices 2nd Edition |
December 2006 | £2230 |
|
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology |
December 2006 | £4515 |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 |
|
CNS Drug Discoveries: Multiple Sclerosis |
November 2006 | £795 |
|
Stakeholder Insight: Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics |
November 2006 | £8000 |
|
Stakeholder Insight: Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics |
November 2006 | £8000 |
|
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD) |
November 2006 | £795 |
|
Commercial and Pipeline Insight: Inflammatory Bowel Disease Competition Increases for the Biologics |
November 2006 | £6000 |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 |
|
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
November 2006 | £6000 |
|
Stakeholder Insight: Non-Small Cell Lung Cancer The need for greater product differentiation in an increasingly crowded market |
November 2006 | £8000 |
|
Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process |
November 2006 | £1000 |
|
Pipeline Insight: Asthma/COPD Targeted therapies on the horizon |
November 2006 | £6000 |
|
Emerging Cancer Vaccine Market, The 2nd Edition |
November 2006 | £2230 |
|
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
October 2006 | £6000 |
|
Hematological Cancers - A Therapeutic & Competitive Insight |
October 2006 | £2575 |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £8000 |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £8000 |
|
Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
October 2006 | £8000 |
|
Stakeholder Insight: Atrial Fibrillation Limited efficacy and poor safety lead to bleak outlook |
October 2006 | £8000 |
|
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology |
October 2006 | £1700 |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £3010 |
|
Leukemia - A Therapeutic & Competitive Insight |
October 2006 | £1700 |
|
World Asthma and COPD Treatment Market, 2006-2011, The A Changing Market with Increasing Potential |
September 2006 | £1499 |
|
Rheumatoid Arthritis: Market Trends and R&D Insights |
September 2006 | £795 |
|
Advanced Life Sciences' Cethromycin Phase III success should allow 'me-too' market entry and above-consensus growth |
September 2006 | £2005 |
|
Pipeline Insight: Insulins Inhalable insulins unlikely to become blockbusters |
September 2006 | £6000 |
|
Commercial Insight: Antihypertensives New challenges for a maturing market |
September 2006 | £8000 |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £6000 |
|
Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm |
September 2006 | £8695 |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £6495 |
|
Psoriasis and Psoriatic Arthritis A Strategic Analysis of the Market in the United States |
September 2006 | £2230 |
|
Emerging Opportunities in Cancer Nanomedicine |
August 2006 | £995 |
|
The Future of Metabolomics Building competitive advantage in drug discovery, clinical development and diagnostics |
August 2006 | £1495 |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £8695 |
|
Pipeline Insight: Non-insulin Antidiabetics Type 2 diabetes unlikely to develop into a switch market |
August 2006 | £6495 |
|
Schizophrenia in Focus |
August 2006 | £29.95 |
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
August 2006 | £1700 |
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology |
August 2006 | £3010 |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £3010 |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1590 |
|
Pipeline Insight: Schizophrenia |
July 2006 | £6330 |
|
Stakeholder Opinions: Parkinson's Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
July 2006 | £2230 |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 |
|
Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies |
July 2006 | £2195 |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £8695 |
|
Advances in Ophthalmology Markets in the Treatment of Eye Disorders and Corrective Vision |
July 2006 | £2480 |
|
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion |
June 2006 | £6495 |
|
Management of Urinary Incontinence and Overactive Bladder A Global Overview |
June 2006 | £8695 |
|
The Pain Market Outlook to 2011 |
June 2006 | £1495 |
|
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011 |
June 2006 | £1495 |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £2195 |
|
Therapeutic Drug Market for Acne Sector Snapshot |
May 2006 | £320 |
|
Diabetes Market Outlook to 2011; The |
May 2006 | £1495 |
|
Dry Overactive Bladder A Precursor to 'Wet Overactive Bladder'? |
April 2006 | £2170 |
|
Interstitial Cystitis Few Treatments, Poor Outcome |
April 2006 | £4340 |
|
Urge Urinary Incontinence Poor Differentiation Limiting New Product Uptake |
April 2006 | £8690 |
|
Stress Urinary Incontinence Opinion Divided on Drug Therapy |
April 2006 | £8690 |
|
Mixed Urinary Incontinence An Opportunity for Novel Drug Therapies |
April 2006 | £6510 |
|
Immunotherapy in Allergic Rhinitis Moving away from injections |
April 2006 | £1430 |
|
Stakeholder Opinions: Kidney Transplantation Switching to calcineurin inhibitor-free immunosuppression |
April 2006 | £2170 |
|
Stakeholder Insight: Metabolic Syndrome Multiple definitions complicate treatment |
April 2006 | £8690 |
|
Stakeholder Opinions: Acute Leukemias Persistent unmet needs confer significant commercial opportunity |
April 2006 | £2170 |
|
Urinary Incontinence and Overactive Bladder The Perspective of the Continence Nurse in the US |
April 2006 | £1090 |
|
Partneringdesk deals and alliances in musculoskeletal diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in cardiovascular diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in genitourinary and gynecological diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in sensory and dental diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in infectious diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in autoimmune & inflammatory diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in metabolic diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in blood and lymphatic diseases |
April 2006 | £1250 |
|
Partneringdesk deals and alliances in gastrointestinal diseases |
April 2006 | £1250 |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 |
|
Global Market for Adjunctive Therapies in Cancer, The 2nd Edition |
April 2006 | £2230 |
|
Stakeholder Opinions: Gastric Cancer Targeted Therapies Home In On a Neglected Tumor Type |
March 2006 | £2195 |
|
Stakeholder Insight: Major Depressive Disorder Duloxetine - Fulfilling An Unmet Need? |
March 2006 | £8695 |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3010 |
|
Stakeholder Opinions: Osteoarthritis Preconceptions Damage Awareness and Treatments |
March 2006 | £2195 |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £6495 |
|
World Diabetes Market, The 2005-2011 |
March 2006 | £1499 |
|
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight |
March 2006 | £1700 |
|
Stakeholder Opinions: Cystic Fibrosis |
March 2006 | £2195 |
|
HIV: A Strategic Analysis of Therapeutic and Testing Markets |
March 2006 | £2230 |
|
Therapeutics for Inflammatory Diseases Current Challenges and Future Market |
March 2006 | £3085 |
|
Stakeholder Perspectives: Pulmonary Arterial Hypertension A small market gets big attention |
February 2006 | £4350 |
|
Urinary Incontinence Markets Sector Snapshot |
January 2006 | £320 |
|
World Gastrointestinal Disorders Market 2006-2011; The |
January 2006 | £1799 |
|
World Market for Sexual Disorders, 2005-2012, The Traversing New Frontiers in Sexual Chemistry |
January 2006 | £795 |
|
Commercial Perspectives: Drug Treatment in End-Stage Renal Disease The Price of Failure |
January 2006 | £4350 |
|
Survey of Private Companies Active in Alzheimer's Drug R&D; A |
January 2006 | £415 |
|
Survey of Private Companies Active in Pain Drug R&D; A |
January 2006 | £415 |
|
Stakeholder Insight: COPD - Another Reason to Quit |
December 2005 | £8695 |
|
Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area |
December 2005 | £795 |
|
World Market for Addiction Disorders 2005-2012, The New Horizons in High-Profile Dependency Markets |
December 2005 | £1100 |
|
Psychopharmacotherapy Market Insights Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012 |
November 2005 | £795 |
|
Prions, CJD, BSE: Industry Background Report List of companies |
October 2005 | £295 |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
October 2005 | £1270 |
|
Breast Cancer: Industry Background Report List of Companies |
October 2005 | £345 |
|
Lung cancer: Industry Background Report List of Companies |
October 2005 | £295 |
|
Colorectal Cancer: Industry Background Report List of Companies |
October 2005 | £295 |
|
Apoptosis: Industry Background Report List of Companies |
October 2005 | £345 |
|
Prostate Cancer: Industry Background Report List of Companies |
October 2005 | £345 |
|
Neuroscience Perspective; The Opportunities for Market Entry & Expansion |
October 2005 | £2865 |
|
PCR: Industry Background Report List of Companies |
October 2005 | £400 |
|
ADME: Industry Background Report List of Companies |
October 2005 | £295 |
|
RNAi, siRNA, microRNA: Industry Background Report List of Companies |
October 2005 | £295 |
|
p53: Industry Background Report List of Companies |
October 2005 | £235 |
|
Pancreatic Cancer: Industry Background Report List of Companies |
October 2005 | £235 |
|
Liver Cancer: Industry Background Report List of Companies |
October 2005 | £235 |
|
Emotional and Behavioral Disorders in Children and Adolescents |
September 2005 | £3085 |
|
Diabetes Monitoring Products & Therapies to 2008 |
February 2005 | £2610 |
|
Analytical Tool: Competitive Outlook on HCV |
July 2004 | £1310 |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £870 |
|
HCV R&D and Business Development Database |
June 2004 | £435 |
|
International Textbook of Diabetes Mellitus |
April 2004 | £310 |
|
Disease Management |
January 2004 | £29.95 |
|
Diabetes in Focus Second edition |
July 2003 | £29.95 |
|
Zoonoses |
April 2002 | £30 |
